Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eletriptan
Drug ID BADD_D00755
Description Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine with or without aura in adults.
Marketing Status Prescription
ATC Code N02CC06
DrugBank ID DB00216
KEGG ID D07887
MeSH ID C115647
PubChem ID 77993
TTD Drug ID D02DMQ
NDC Product Code Not Available
Synonyms eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide
Chemical Information
Molecular Formula C22H26N2O2S
CAS Registry Number 143322-58-1
SMILES CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vasospasm24.04.02.002--Not Available
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.001656%
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.0030.011595%
Weight decreased13.15.01.0050.003313%
Weight increased13.15.01.006--
Yawning22.02.05.017--Not Available
Deep vein thrombosis24.01.02.0030.002485%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Breast cancer female21.05.01.011; 16.10.01.0040.001656%Not Available
Major depression19.15.01.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.001656%Not Available
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.01.0190.001656%Not Available
Mental disorder19.07.01.0020.002485%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Lacrimal disorder06.08.02.005--Not Available
Autoimmune disorder10.04.04.0030.001656%
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Increased bronchial secretion22.02.04.007--Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages